Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb;4(3-4):61-71.
doi: 10.1159/000481797. Epub 2017 Nov 23.

Effects of Enteral Immunonutrition in Esophageal Cancer

Kenji Mimatsu  1 , Nobutada Fukino  1 , Yasuo Ogasawara  1 , Yoko Saino  2 , Takatsugu Oida  3
Affiliations
Review

Effects of Enteral Immunonutrition in Esophageal Cancer

Kenji Mimatsu et al. Gastrointest Tumors. 2018 Feb.

Abstract

Background: Immunonutrition (IN) significantly reduces the incidence of postoperative infectious complications and the length of hospitalization in patients undergoing major elective surgery for gastrointestinal malignances. However, the clinical benefit of IN in patients who have undergone esophagectomy for esophageal cancer is unclear. Moreover, the effect of enteral IN in patients during preoperative adjuvant chemoradiotherapy and in patients treated with concurrent chemoradiotherapy for advanced esophageal cancer is unknown.

Summary: This review analyzes the evidence supporting the enteral administration of IN in patients who have undergone esophagectomy and/or chemoradiotherapy for esophageal cancer. Twelve trials that evaluated IN exclusively in patients who underwent esophagectomy were published between January 1980 and August 2017. Two trials concerning IN during chemoradiotherapy for esophageal cancer were identified in the same period. However, the evidence is insufficient to recommend enteral IN in patients who have undergone esophagectomy and/or chemoradiotherapy for esophageal cancer.

Key message: Further evidence from well-designed randomized controlled trials is required to verify the clinical benefits of enteral IN in patients undergoing esophagectomy and/or chemoradiotherapy for esophageal cancer.

Practical implications: Resolvins, which are generated from EPA, are novel anti-inflammatory lipid mediators and may play a key role in the resolution of acute inflammation when IN is supplemented with EPA in patients undergoing severely stressful operations.

Keywords: Chemoradiotherapy; Esophageal cancer; Immunonutrition; Surgery.

PubMed Disclaimer

References

    1. Bozzetti F. Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support Care Cancer. 2009;17:279–284. - PubMed
    1. Daly JM, Fry WA, Little AG, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000;190:562–572. discussion 572–573. - PubMed
    1. Van der Schaaf MK, Tilanus HW, van Lanschot JJ, et al. The influence of preoperative weight loss on the postoperative course after esophageal cancer resection. J Thorac Cardiovasc Surg. 2014;147:490–495. - PubMed
    1. Correia MI, Caiaffa WT, da Silva AL, et al. Risk factors for malnutrition in patients undergoing gastroenterological and hernia surgery: an analysis of 374 patients. Nutr Hosp. 2001;16:59–64. - PubMed
    1. Marin FA, Lamônica-Garcia VC, Henry MA, et al. Grade of esophageal cancer and nutritional status impact on postsurgery outcomes. Arq Gastroenterol. 2010;47:348–353. - PubMed